Laboratory Screening for Pediatric Obesity
Core Laboratory Tests by Age and BMI Category
- Children with obesity (BMI ≥95th percentile) should be screened with a lipid panel starting at age 2 years, fasting glucose at age 10 years, and ALT for NAFLD screening between ages 9-11 years, with additional metabolic testing based on age and comorbidity burden, as recommended by the American Academy of Pediatrics 1, 2
- The American Academy of Pediatrics recommends obtaining a fasting lipid profile (total cholesterol, LDL, HDL, triglycerides) for children with obesity, with confirmation of abnormal values 2 weeks to 3 months after initial screen 1, 2, 3
- For children with obesity, glucose screening should start at age 10 years, using fasting glucose as the screening test, and considering additional risk factors such as family history of type 2 diabetes, signs of insulin resistance, or presence of other metabolic syndrome components 1, 2
Liver Function Testing (NAFLD Screening)
- The American Association for the Study of Liver Diseases recommends screening children aged 9-11 years with obesity using ALT, with gender-specific thresholds (ALT ≥26 IU/L for boys, ≥22 IU/L for girls) suggesting NAFLD 4, 5
- For NAFLD screening, AST can be included but ALT is the preferred screening test, and abdominal ultrasound should be considered when ALT is elevated or when additional confirmation is needed 4, 5
Additional Laboratory Considerations
- When ALT is elevated (suggesting NAFLD), AST should also be measured if not already done, and consider additional non-invasive assessment with abdominal ultrasound, liver fibrosis scans, or MRI-PDFF for further evaluation 4, 5
Important Clinical Caveats
- The American Academy of Pediatrics suggests that NAFLD screening before age 9 may be appropriate when risk is particularly high (strong family history, severe obesity, metabolic syndrome), though no specific algorithm exists for defining this high-risk group 1, 2
- Normal ALT does not exclude NAFLD, with a sensitivity of only approximately 50% at commonly used thresholds, and ALT correlates with steatosis and insulin resistance rather than inflammation or fibrosis 6, 7